Consortium.AI (IMAGE)

InSilico Medicine

Consortium.AI

Caption

Insilico Medicine announced a research collaboration agreement with A2A Pharmaceuticals, Inc. The two parties agreed to create a new company called 'Consortium.AI', which will apply the latest advances in AI to discovery of novel small molecules for the Duchenne Muscular Dystrophy (DMD) and other rare orphan diseases.

Credit

Insilico Medicine, Inc.

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.